Serum lipoproteins in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications cohort: Associations with gender and glycemia

Diabetes Care

Volumn 26, Issue 3, 2003, Pages 810-818

  Jenkins, Alicia J ^a   Lyons, Timothy J ^a   Zheng, Deyi ^a   Otvos, James D ^b   Lackland, Daniel T ^a   McGee, Daniel ^a   Garvey, W Timothy ^a,c   Klein, Richard L ^a,c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGE; ANTHROPOMETRY; ARTICLE; ATHEROGENESIS; BODY MASS; CALCULATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIABETES CONTROL; DISEASE ASSOCIATION; DISEASE DURATION; DISEASE PREDISPOSITION; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE; PROTEINURIA; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

ADULT; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CHOLESTEROL, VLDL; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; LIPOPROTEINS; LIPOPROTEINS, LDL; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; RISK FACTORS; SEX DISTRIBUTION; TRIGLYCERIDES;

EID: 0042905925     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.3.810     Document Type: Article

References (49)

1. Herman WH, Crofford OB: Diabetic Control and Complications. In Chronic Complication of Diabetes. Pickup JC, Williams G, Eds. Melbourne, Blackwell Press, 1994, p. 41.1-41.11
2. Pyorala K: Diabetes and heart disease. In Prevention and Treatment of the Diabetic Late Complications. Mogensen CE, Standl E, Eds. New York, Walter de Gruyter, 1989, p. 151-168
3. Taskinen MR: Hyperlipidaemia in diabetes. In Lipid and Lipoprotein Disorders Bailliere's Clinical Endocrinology and Metabolism. Betteridge DJ, Ed. London, 1990, p. 743-775
4. Tomkin GH, Owens D: Insulin and lipoprotein metabolism with special reference to the diabetic state. Diabete Metab Rev 10:225-252, 1994
5. Lyons TJ, Klein RL, Baynes JW, Stevenson HC, Lopes-Virella MF: Stimulation of cholesteryl ester synthesis in human monocyte-derived macrophages by lipoproteins from type I diabetic subjects: the influence of non-enzymatic glycosylation of low-density lipoproteins. Diabetologia 30:916-923, 1987
6. Lyons TJ: Oxidized low density lipoproteins: a role in the pathogenesis of atherosclerosis in diabetes? Diabet Med 8:411-419, 1991
7. Austin MA, Breslow JL, HeMekens CH, Buring JE, Willet WC, Krauss RM: Low density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260:1917-1921, 1988
8. Havel RJ: Role of triglyceride-rich lipoproteins in progression of atherosclerosis. Circulation 82:694-696, 1990
9. Fievet C, Fruchart JC: HDL heterogeneity and coronary heart disease. Diabete Metab Rev 7:155-162, 1991
10. Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP: Associations of HDL2 and HDL3 ischemic heart disease in men: prospective results for the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 17:1098-1105, 1997
11. Sibley SD, Hokanson JE, Steffes MW, Purnell JQ, Marcovina SM, Cleary PA, Brunzell JD: Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes. Diabetes Care 22:1165-1170, 1999
12. O'Neal D, Harrip P, Dragicevic G, Rae D, Best JD: A comparison of LDL size determination using gradient gel electrophoresis and light-scattering methods. J Lipid Res 39:2086-2090, 1999
13. Austin MA, Hokanson JE, Brunzell JD: Characterization of LDL subclasses: methodologic approaches and clinical relevance (Review Article). Curr Opin Lipidol 5:395-403, 1994
14. Purnell JQ, Marcovina SM, Hokanson JE, Kennedy H, Cleary PA, Steffes MW, Brunzell JD: Levels of lipoprotein(a), apolipoprotein B, and lipoprotein cholesterol distribution in IDDM: results from follow-up in the Diabetes Control and Complications Trial. Diabetes 44:1218-1226, 1995
15. Otvos JD: Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. In Handbook of Lipoprotein Testing. Rifai N, Warnick G, Dominiczak MH, Eds. Washington, DC, AACC Press, 1997, p. 497-508
16. The DCCT Research Group: Feasibility of centralized measurements of glycated hemoglobin in the Diabetes Control and Complications Trial: a multicenter study. Clin Chem 33:2267-2271, 1987
17. The DCCT Research Group: The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 329:977-986, 1993
18. Epidemiology of Diabetes Interventions and Complications (EDIC): Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 22:99-111, 1999
19. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group: Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381-389, 2000
20. Lyons TJ, Otvos JD, Klein RL, Zheng D, Garvey WT, Jenkins AJ, the DCCT/EDIC Research Group: Nuclear magnetic resonance (NMR)-determined lipoprotein subclass profile: effects of hyperglycemia, lipoprotein glycation, and comparison with standard lipid profile (Abstract). Diabetes 49 (Suppl. 1):1117P, 2000
21. Jenkins AJ, Klein RL, Chassereau C, Hermayer KL, Lopes-Virella M: Susceptibility to in vitro oxidation of LDL from patients with well-controlled IDDM is not increased. Diabetes 45:762-767, 1996
22. Couture P, Otvos JD, Cupples LA, Wilson PWF, Schaefer EJ, Ordovas JM: Association of the A-204C polymorphism in the cholesterol 7α-hydroxylase gene with variations in plasma low density lipoprotein cholesterol levels in the Framingham Offspring Study. J Lipid Res 40:1883-1889, 1999
23. American Diabetes Association: Standards of medical care for patients with diabetes mellitus (Position Statement). Diabetes Care 25 (Suppl. 1):S33-S49, 2002
24. Lyons TJ, Jenkins AJ: Lipoprotein glycation and its metabolic consequences. Curr Opin Lipidol 8:174-180, 1997
25. Lamavche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupen PJ, Despres JP: Small, dense, low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Circulation 95:69-75, 1997
26. Lahdenpera, Groop PH, Tilly-Kiesi M, Kuusi T, Elliott TG, Viberti GC, Taskinen MR: LDL subclasses in IDDM patients: relation to diabetic nephropathy. Diabetologia 37:681-688, 1994
27. Gianturco SH, Bradley WA: Pathophysiology of triglyceride-rich lipoproteins in atherothrombosis: cellular aspects. Clin Cardiol 22 (Suppl. 6):II7-II14, 1999
28. Maeno Y, Kashiwagi A, Nishio Y, Takahara N, Kikkawa R: IDL can stimulate atherogenic gene expression in cultured human vascular endothelial cells. Diabetes Res Clin Pract 48:127-138, 2000
29. Lipinska I, Gurewich V, Meriam CM, Kosowsky BD, Ramaswamy K, Philbin E, Losordo D: Lipids, lipoproteins, fibrinogen and fibrinolytic activity in angiographically assessed coronary heart disease. Artery 15:44-60, 1987
30. Hodis HN, Mack WJ, Dunn M, Liu C, Liu C, Selzer RH, Krauss RM: Intermediate-density lipoproteins and progression of carotid arterial wall intima-media thickness. Circulation 95:2022-2026, 1997
31. Fagot-Capmagna A, Narayan KMV, Hanson RL, Imperatore G, Howard BV, Nelson RG, Pettitt DJ, Knowler WC: Plasma lipoproteins and incidence of NIDDM in Pima Indians: protective effect of HDL cholesterol in women. Atherosclerosis 128:113-119, 1997
32. Klein R, Klein BE, Moss SE, Cruickshanks KJ, Brazy PC: The 10-year incidence of renal insufficiency in people with type 1 diabetes. Diabetes Care 22:743-751, 1999
33. Andersson LO: Pharmacology of apolipoprotein A-1. Curr Opin Lipid 8:225-228, 1997
34. Barter PJ, Rye KA: High density lipoproteins and coronary heart disease. Atheroscler 121:1-12, 1996
35. Williams PT, Krauss RM, Vranizan KM, Stefanick ML, Wood PD, Lindgren FT: Associations of lipoproteins and apolipoproteins with gradient gel electrophoresis estimates of high density lipoprotein subfractions in men and women. Arterioscler Thromb 12:332-340, 1992
36. Freedman DS, Bowman BA, Srinivasan SR, Berenson GS, Otvos JD: Distribution and correlates of high-density lipoprotein subclasses among children and adolescents. Metabolism 50:370-376, 2001
37. Lloyd CE, Kuller LH, Ellis D, Becker DJ, Wing RR, Orchard TJ: Coronary artery disease in IDDM: gender differences in risk factors but not risk. Arterioscler Thromb Vasc Biol 16:720-726, 1996
38. Helisten H, Hockerstedt A, Wahala K, Tiitinen A, Adlercreutz H, Jauhiainen M, Tikkanen MJ: Accumulation of high-density lipoprotein-derived estradiol-17beta fatty acid esters in low-density lipoprotein particles. J Clin Endocrinol Metab 86:1294-1300, 2001
39. Wakatsuki A, Ikenoue N, Okatani Y, Fukaya T: Estrogen-induced small low density lipoprotein particles may be atherogenic in postmenopausal women. J Am Coll Cardiol 37:425-430, 2001
40. Klein RL, Laimins M, Lopes-Virella MF: Isolation, characterization, and metabolism of the glycated and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and nondiabetic subjects. Diabetes 44:1093-1098, 1995
41. De Rijke YB, Verwey HF, Vogelezang CJ, Van Der Velde EA, Princen HM, Van Der Laarse A, Bruschke AV, Van Berkel TJ: Enhanced susceptibility of low-density lipoproteins to oxidation in coronary bypass patients with progression of atheroscerosis. Clin Chim Acta 243:137-149, 1995
42. Chiu HC, Jeng JR, Shieh SM: Increased oxidizability of plasma low density lipoprotein from patients with coronary artery disease. Biochim Biophys Acta 1225:200-208, 1994
43. Waters D, Pedersen TR: Review of cholesterol-lowering therapy: coronary angiographic and events trials. [Discussion, 101 (4A):39S] Am J Med 101 (4A):34S-38S, 1996
44. Boden WE: High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 86:19-22, 2000
45. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA: Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. Arterioscler Thromb Vasc Biol 18:1046-1053, 1998
46. Rosenson RS, Freedman DS, Otvos JD: Relations of lipoprotein subclass levels and LDL size to progression of coronary artery disease in the PLAC I trial. Am J Cardiol 90:89-94, 2002
47. Mackey RH, Kuller LH, Sutton-Tyrrell K, Evans RW, Holubkov R, Matthews KA: Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the Healthy Women Study. Am J Cardiol 90:71i-76i, 2002
48. Lyons TJ, Otvos JD, Klein RL, Zheng D, Garvey WT, Jenkins AJ, the DCCT/EDIC Research Group: Nuclear magnetic resonance (NMR)-determined lipoprotein subclass profile: associations with subclinical macrovascular disease. In Abstract Book of International Diabetes Federation. Mexico, IDF, 2000
49. Lyons TJ, Zheng D, Otvos JD, Klein RL, Lackland DT, Garvey WT, Jenkins AJ, the DCCT/EDIC Research Group: Nuclear magnetic resonance (NMR)-determined lipoprotein subclass profile in the DCCT/EDIC cohort: associations with retinopathy and nephropathy (Abstract). Diabetes 49 (Suppl. 1):1118P, 2000